



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 231/02	A1	(11) International Publication Number: WO 98/27052 (43) International Publication Date: 25 June 1998 (25.06.98)
<p>(21) International Application Number: PCT/SE97/02092</p> <p>(22) International Filing Date: 12 December 1997 (12.12.97)</p> <p>(30) Priority Data: 9626319.9 19 December 1996 (19.12.96) GB</p> <p>(71) Applicant (for all designated States except MG US): ASTRA PHARMACEUTICALS LTD. [GB/GB]; Home Park, Kings Langley, Herts WD4 8DH (GB).</p> <p>(71) Applicant (for MG only): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): HARRIS, Alan, Richard [GB/GB]; 63 Trueway Drive, Shepshed, Leicestershire LE12 9HG (GB).</p> <p>(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>

(54) Title: PROCESS FOR THE PREPARATION OF NMDA ANTAGONISTS

(57) Abstract

This invention relates to an improved process for the production of known amine compounds of formula (I) which are useful as medicaments, wherein: R¹ and R² are independently phenyl or 4-fluorophenyl; R³ is hydrogen, alkyl C₁₋₄ or methoxycarbonyl; R⁴ is hydrogen or methyl; which comprises reaction of a compound of formula (II) with a compound of formula (III) in which R⁵, R⁶, R⁷, R⁸, R⁹ and R¹⁰ are independently C₁₋₆ alkyl followed by de-protection and optionally thereafter forming a pharmaceutically acceptable salt.

